Botox Spasticity denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for botox spasticity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits the Quantity of OnabotulinumtoxinA (Botox) for Spasticity — and How to Appeal

Humana's quantity-limit policy for onabotulinumtoxinA (Botox) in spasticity restricts the total amount of the drug that may be approved per treatment session or per benefit period. Denials in this category arise when the prescribing physician's injection plan requests an amount that exceeds Humana's coverage threshold — which is typically expressed as a per-session or annual cap defined in its published medical policy. The requested quantity may still be entirely within the FDA-approved labeling and within the range endorsed by professional society guidelines, yet still exceed Humana's plan-specific limit.

Quantity-limit denials are appealed by demonstrating that (a) the requested amount is clinically necessary for the patient's specific muscle involvement and body mass, (b) the amount is within the FDA-approved labeling, and (c) Humana's limit is inconsistent with the treating physician's individualized clinical judgment.

## Federal Appeal Framework

ACA §2719 provides internal appeal and, upon internal denial, independent external review by an IRO. ERISA §503 provides full-and-fair review for self-funded plans. The external review window is approximately four months from the final internal denial. If the delay in treatment is causing functional deterioration, request expedited review — a decision is required within 72 hours.

## Concrete Appeal Steps and Timeline

1. Request Humana's quantity-limit policy for Botox in spasticity to identify the specific cap being applied. 2. Verify that the requested amount is within the FDA-approved prescribing information — obtain the current label from FDA.gov or the manufacturer. Note the approved dosing range without including specific numbers in your appeal narrative. 3. File the Level 1 internal appeal within the deadline on your denial notice. 4. If Level 1 fails, proceed to Level 2 or IRO external review. 5. Ask the IRO to determine whether Humana's quantity limit is consistent with the FDA label and with accepted medical practice for the patient's documented muscle involvement.

## Documentation to Gather

• Diagnosis confirmation: chart documentation of the neurological condition and the specific muscle groups targeted for injection
• Injection planning note: the physiatrist's or neurologist's written plan specifying each targeted muscle, the rationale for the volume allocated to each, and how the total is determined by the patient's anatomy and clinical presentation — not by preference
• FDA label reference: confirmation that the requested amount falls within the approved labeling range (attach relevant label pages)
• Prior session records: if prior injections were given at lower quantities with documented suboptimal response, include those visit notes
• Clinical severity: spasticity scale scores, functional assessments, and documentation of impairment
• Prescriber medical-necessity letter explaining the clinical basis for the requested quantity and addressing Humana's limit

## Criteria-Mapping Structure

Address the quantity-limit denial point by point:

| Quantity-Limit Issue | Clinical Response | |---|---| | Amount exceeds Humana's per-session cap | [Confirm amount per FDA label range; prescriber explains clinical necessity] | | Number of muscle groups justifying total requested | [Injection plan listing each targeted muscle and rationale] | | Prior response at lower quantity (if applicable) | [Prior visit note documenting inadequate response at lesser amount] | | FDA label consistency | [Label pages confirming the requested amount is within approved range] |

A detailed injection-planning note from the treating specialist is the single most important document for quantity-limit appeals — it transforms the request from an abstract number into a clinically justified treatment plan.